Viatris announces publication of phase 2b care study data for cenerimod in lancet rheumatology

Biomarker data from care study characterizing cenerimod's mechanism of action in systemic lupus erythematosus also published in the annals of the rheumatic diseases pittsburgh , dec. 18, 2024 /prnewswire/ --  viatris inc.  (nasdaq: vtrs) today announced the publication of phase 2b care study results evaluating the efficacy and safety of cenerimod in adults with moderate-to-severe systemic lupus erythematosus (sle). the results, published in lancet rheumatologyi , showed cenerimod 4 mg demonstrated clinically meaningful and sustained improvement from baseline on multiple measures of sle disease activity compared to placebo, in addition to stable background sle therapy.
VTRS Ratings Summary
VTRS Quant Ranking